XML 22 R9.htm IDEA: XBRL DOCUMENT v3.25.1
Revenue
12 Months Ended
Dec. 31, 2024
Revenue  
Revenue

2.Revenue

The Company launched LOQTORZI in December 2023, YUSIMRY in July 2023 and CIMERLI in October 2022. Net revenue for sales of YUSIMRY and CIMERLI effectively ceased following the disposition of these two product lines on June 26, 2024 and March 1, 2024, respectively (see Note 6. Acquisition and Dispositions). All net product revenue was generated in the United States, and the Company’s net revenue was as follows:

Year Ended December 31, 

(in thousands)

    

2024

2023

2022

Products

UDENYCA

$

205,951

$

127,064

$

203,814

CIMERLI

27,079

125,388

6,946

YUSIMRY

7,541

3,574

LOQTORZI

19,131

554

Total net product revenue

259,702

256,580

210,760

Other revenue

 

7,258

 

664

 

282

Total net revenue

$

266,960

$

257,244

$

211,042

Gross product revenues by significant customer as a percentage of total gross product revenues were as follows:

    

Year Ended December 31,

 

2024

2023

 

2022

 

McKesson Corporation

 

42

%

40

%

38

%

Cencora (previously known as AmeriSource-Bergen Corporation)

 

38

%

43

%

44

%

Cardinal Health, Inc.

 

18

%

15

%

17

%

Product Sales Discounts and Allowances

Chargebacks and discounts for prompt payment are recorded as a reduction in trade receivables, and the remaining reserve balances are classified as current liabilities and other liabilities, non-current on the accompanying consolidated balance sheets.

In connection with the Sale Transactions, the Company retained and will continue to be responsible for sales discounts and allowance liabilities incurred related to shipments prior to March 1, 2024 for CIMERLI and June 26, 2024 for YUSIMRY. Sales discounts and allowances incurred on behalf of the respective counterparties following the close of the Sale Transactions in accordance with the Company’s Transition Services Agreement with Sandoz (the “CIMERLI TSA”) in March 2024 for CIMERLI and the Company’s Transition Services Agreement with HKF (the “YUSIMRY TSA” and, together with the CIMERLI TSA, collectively the “TSA”) in June 2024 for YUSIMRY are reflected within TSA receivables, net and TSA payables and other accrued liabilities in the consolidated balance sheets and are excluded from the below table (see Note 6. Acquisition and Dispositions).

The activities and ending reserve balances for each significant category of sales discounts and allowances, which constitute variable consideration, are as follows:

    

Chargebacks

    

    

Other Fees,

    

and Discounts

Co-pay

for Prompt

Assistance

(in thousands)

Payment

Rebates

and Returns

Total

Balances at December 31, 2021

$

29,665

$

54,004

$

26,054

$

109,723

Provision related to sales made in:

Current period

 

436,865

68,399

73,435

578,699

Prior period - increase (decrease)

(2,090)

(1,050)

32

(3,108)

Payments and customer credits issued

 

(421,763)

(82,640)

(80,408)

 

(584,811)

Balances at December 31, 2022

42,677

38,713

19,113

100,503

Provision related to sales made in:

Current period

590,772

143,370

110,183

844,325

Prior period - increase (decrease)

(1,361)

1,424

3,744

3,807

Payments and customer credits issued

(558,135)

(62,370)

(83,245)

(703,750)

Balances at December 31, 2023

73,953

121,137

49,795

244,885

Provision related to sales made in:

Current period

912,079

189,309

145,533

1,246,921

Prior period - increase (decrease)

(990)

7,391

(2,571)

3,830

Payments and customer credits issued

 

(874,264)

(194,099)

(151,628)

(1,219,991)

Balances at December 31, 2024

$

110,778

$

123,738

$

41,129

$

275,645